Cargando…
Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report
BACKGROUND: Waldenström’s macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström’s macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but not idel...
Autores principales: | D’Aveni-Piney, M., Divoux, M., Busby-Venner, H., Muller, M., Broséus, J., Feugier, P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996512/ https://www.ncbi.nlm.nih.gov/pubmed/29890999 http://dx.doi.org/10.1186/s13256-018-1694-z |
Ejemplares similares
-
Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome
por: Ojeda-Uribe, Mario, et al.
Publicado: (2020) -
Membranoproliferative glomerulonephritis complicating Waldenström’s macroglobulinemia
por: Kratochvil, David, et al.
Publicado: (2012) -
Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia
por: Dogliotti, Irene, et al.
Publicado: (2022) -
Pseudohyperphosphatemia in Waldenstrom's Macroglobulinemia
por: Amalnath, S. D., et al.
Publicado: (2013) -
Waldenstrom’s Macroglobulinemia: An Update
por: Mazzucchelli, Maddalena, et al.
Publicado: (2018)